AVEO Oncology to Present at Upcoming Conferences
March 26 2018 - 4:05PM
Business Wire
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey,
president and chief executive officer, will present at the
following investor conferences:
- Needham & Company’s 17th Annual
Healthcare Conference on Wednesday, March 28, 2018 at 8:00 a.m.
Eastern Time. The conference is being held at the Westin Grand
Central Hotel in New York, New York.
- H.C. Wainwright Global Life Sciences
Conference on Tuesday, April 10, 2018 at 10:40 a.m. Central
European Summer Time. The conference is being held at the Le
Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
A live webcast of the presentations can be accessed by visiting
the investors section of the Company’s website at
www.aveooncology.com. A replay of the webcast will be archived for
30 days following the presentation date.
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology
and other areas of unmet medical need. The Company is focused on
seeking to develop and commercialize its lead candidate tivozanib,
a potent, selective, long half-life inhibitor of vascular
endothelial growth factor 1, 2 and 3 receptors, in North America as
a treatment for renal cell carcinoma and other cancers. AVEO is
leveraging multiple partnerships aimed at developing and
commercializing tivozanib in oncology indications outside of North
America, and at progressing its pipeline of novel therapeutic
candidates in cancer and other areas of unmet medical need.
Tivozanib (FOTIVDA®) is approved by the European Commission for the
treatment of adult patients with advanced renal cell carcinoma in
the European Union plus Norway and Iceland. For more information,
please visit the Company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements
of AVEO that involve substantial risks and uncertainties.
All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Actual
results or events could differ materially due to a number of
important factors, including risks discussed in the section titled
“Risk Factors” in AVEO’s most recent Annual Report on Form 10-K,
its quarterly reports on Form 10-Q and its other filings with
the SEC. The forward-looking statements in this press release
represent AVEO’s views as of the date of this press
release. AVEO anticipates that subsequent events and
developments may cause its views to change.
While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180326005956/en/
AVEO:Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jul 2024 to Aug 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2023 to Aug 2024